GlassScriptPhysician profile
Megan Brooke Wolf
NPI 1538743877
$2,841.31
in general payments reported to CMS, 2019-2025
34 companies · $718 in 2025
The $718 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4.30 · 2022: $280 · 2023: $1,175 · 2024: $663 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $496.20 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $355.66 | 2023-2025 | |
| Lilly USA, LLC | $270.59 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $184.77 | 2023-2025 | |
| Corium, LLC | $169.76 | 2022-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.65 | 2023-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $134.76 | 2022-2025 | |
| Exact Sciences Corporation | $129.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $117.40 | 2023-2025 | Auvelity, Symbravo |
| Amgen INC. | $98.85 | 2022-2025 | Evenity, Prolia |
| Idorsia Pharmaceuticals US INC | $54.92 | 2023 | Quviviq |
| Shield Therapeutics INC | $51.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.08 | 2022-2023 | Trintellix |
| Impel Pharmaceuticals INC. | $43.90 | 2023 | Trudhesa |
| Astellas Pharma US INC | $43.73 | 2023-2024 | Veozah |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $43.49 | 2023-2024 | Xelstrym |
| Astrazeneca Pharmaceuticals LP | $42.58 | 2023-2024 | Farxiga, Breztri |
| Tris Pharma INC | $40.16 | 2023-2024 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $36.97 | 2022-2023 | Rexulti |
| Abbott Laboratories | $36.07 | 2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $32.77 | 2022-2023 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.92 | 2025 | |
| Neos Therapeutics, LP | $28.00 | 2022-2023 | Adzenys Xr-Odt |
| Inspire Medical Systems, INC. | $24.70 | 2025 | Inspire |
| Saluda Medical Americas, INC. | $24.13 | 2024 | Evoke |
| Sanofi-Aventis U.S. LLC | $22.11 | 2025 | |
| Daiichi Sankyo INC. | $21.68 | 2022 | |
| Esperion Therapeutics, INC. | $21.66 | 2025 | Nexletol |
| Biotronik Nro, INC. | $20.32 | 2024 | Prospera |
| Medtronic, INC. | $19.23 | 2024 | Interstim |
| Antares Pharma, INC. | $17.24 | 2025 | Xyosted |
| Sanofi Pasteur INC. | $17.02 | 2023 | |
| Glaxosmithkline, LLC. | $13.60 | 2023 | Arexvy, Shingrix |
| Genentech USA, INC. | $4.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.